Discounted Cash Flow
Ascentage Pharma Group International Foreign
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2012 | $54.4k | — | — | — | $-0.00 |
| 2013 | $15 (-100.0%) | $-155.0k | $-120.5k | -1033166.7% | $-0.00 |
| 2014 | $0 (-100.0%) | $-782.4k (-404.9%) | $-7.0k (94.2%) | — | $-0.01 |
| 2015 | $0 | $-282.9k (63.8%) | $-97.7k (-1294.8%) | — | $-0.00 (100.0%) |
| 2016 | $0 | $-1.5m (-440.9%) | $-882.4k (-803.1%) | — | $-0.01 |
| 2021 | — | — | — | — | $-12.28 (-122700.0%) |
| 2022 | $209.7m | $-3 | $-692.1m | -0.0% | $-3.35 (72.7%) |
| 2023 | $222.0m (5.9%) | $-925.6m (-27630955123.9%) | $-781.4m (-12.9%) | -417.0% (-26103301268.4%) | $-3.28 (2.1%) |
| 2024 | $134.3m (-39.5%) | $-55.5m (94.0%) | $-182.5m (76.6%) | -41.3% (90.1%) | $-0.18 (94.5%) |
| 2025 | $574.1m (327.3%) | $-3 (100.0%) | $-1.2b (-579.2%) | -0.0% (100.0%) | $-3.49 (-1838.9%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Values abbreviated: b = billions, m = millions, k = thousands.
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.